Press Releases

June 9, 2021 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
May 10, 2021 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 In negotiations with multiple regulatory authorities regarding ARCT-021 Phase 3 study program Continued progress advancing mRNA therapeutic

PDF Version
May 3, 2021 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

SAN DIEGO --(BUSINESS WIRE)--May 3, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
March 30, 2021 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
March 1, 2021 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

ARCT-021 single-shot COVID-19 STARR™ mRNA vaccine to be advanced to Phase 3 clinical development – on track to initiate Phase 3 study in Q2 ARCT-021 single shot immunogenicity profile compares favorably with new data generated from recipients of a single dose of an approved conventional mRNA

PDF Version 395.7 KB
February 22, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
February 19, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

SAN DIEGO --(BUSINESS WIRE)--Feb. 19, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
February 11, 2021 at 8:30 AM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Feb. 11, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
January 6, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version 140.7 KB
January 4, 2021 at 7:01 AM EST

Summary Toggle Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Phase 2 study to be conducted in the U.S. and Singapore , and will evaluate both single dose and two dose priming regimens of ARCT-021 in up to 600 participants Anticipate interim Phase 2 data in early 2021; targeting global Phase 3 study start in Q2 2021 which could allow application for emergency

PDF Version